Advertisement

Psychopharmacology

, Volume 231, Issue 2, pp 327–332 | Cite as

Cortical glutathione levels in young people with bipolar disorder: a pilot study using magnetic resonance spectroscopy

  • Beata R. Godlewska
  • Sarah W. Yip
  • Jamie Near
  • Guy M. Goodwin
  • Philip J. Cowen
Original Investigation

Abstract

Rationale

Glutathione (GSH) is a key scavenger for cellular free radicals, and patients with bipolar disorder may have lowered GSH levels in plasma and in post-mortem brain tissue.

Objectives

The objective of the current study was to use magnetic resonance spectroscopy (MRS) to measure cortical GSH levels in young people with bipolar disorder to determine if lowered GSH might be a useful biomarker of vulnerability to the illness.

Methods

We studied 13 patients with DSM-IV bipolar disorder and 11 healthy age-matched controls using proton MRS in conjunction with the SPECIAL acquisition technique. Voxels were placed in prefrontal and occipital cortex. All patients were clinically euthymic at the time of study and unmedicated. GSH and other relevant neurometabolites were measured relative to creatinine.

Results

There was no difference in GSH levels between bipolar participants and controls in either prefrontal or occipital cortex. Similarly, participants showed no difference from controls in other measured cortical metabolites including γ-aminobutyric acid, glutamate and N-acetylaspartate.

Conclusions

This pilot study suggests that levels of cortical GSH are unlikely to be a useful trait biomarker of bipolar disorder in young people with a history of relatively mild mood instability at an early stage of illness. Lowered GSH levels may be relevant to bipolar pathophysiology in more severely ill patients, particular those with significant current mood disturbance.

Keywords

Bipolar disorder Oxidative stress Glutathione Magnetic resonance spectroscopy (MRS) 

Notes

Conflicts of interest

This study was funded by the Medical Research Council. Philip J. Cowen has been a paid advisor of Lundbeck and Servier and has been a paid lecturer for Lundbeck, Servier and Glaxo Smith Kline. Guy M. Goodwin has held grants from Servier, received honoraria for speaking or chairing educational meeting from AstraZeneca, BMS, Eisai, Lundbeck, Servier and advised AstraZeneca, Boehringer Ingelheim, BMS, Cephalon/Teva Janssen Cilag, Lilly, Lundbeck, Otsuka, P1Vital, Servier, Shire, Takeda and Pfizer. He holds shares in P1vital and acted as expert witness for Lilly. Beata R. Godlewska, Sarah W. Yip and Jamie Near have no conflict of interest to declare.

References

  1. Berk M, Ng F, Dean O, Dodd S, Bush AI (2008) Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 29:346–351PubMedCrossRefGoogle Scholar
  2. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS (2011a) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35:804–817. doi: 10.1016/j.neubiorev.2010.10.001 PubMedCrossRefGoogle Scholar
  3. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS (2011b) The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 135:389–394. doi: 10.1016/j.jad.2011.06.005 PubMedCrossRefGoogle Scholar
  4. Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Boorman E, Matthews PM, Cowen PJ (2008) Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 11:255–260PubMedCrossRefGoogle Scholar
  5. Cui J, Shao L, Young LT, Wang JF (2007) Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144:1447–1453PubMedCrossRefGoogle Scholar
  6. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Yatham LN, Young LT (2011) Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int J Neuropsychopharmacol 14:1069–1074. doi: 10.1017/S1461145711000617 PubMedCrossRefGoogle Scholar
  7. Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN (2012) Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord 14:478–487. doi: 10.1111/j.1399-5618.2012.01033.x PubMedCrossRefGoogle Scholar
  8. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg 23:56–62CrossRefGoogle Scholar
  9. Hermens DF, Lagopoulos J, Naismith SL, Tobias-Webb J, Hickie IB (2012) Distinct neurometabolic profiles are evident in the anterior cingulate of young people with major psychiatric disorders. Transl Psychiatry 2:e110. doi: 10.1038/tp.2012.35 PubMedCentralPubMedCrossRefGoogle Scholar
  10. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE Jr, Lewis L, McElroy SL, Post RM, Rapport DJ, Russell JM, Sachs GS, Zajecka J (2000) Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psych 157:1873–1875CrossRefGoogle Scholar
  11. Lewinsohn PM, Shankman SA, Gau JM, Klein DN (2004) The prevalence and co-morbidity of subthreshold psychiatric conditions. Psychol Med 34:613–622PubMedCrossRefGoogle Scholar
  12. Mekle R, Mlynárik V, Gambarota G, Hergt M, Krueger G, Gruetter R (2009) MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 61:1279–1285. doi: 10.1002/mrm.21961 PubMedCrossRefGoogle Scholar
  13. Near J, Andersson J, Maron E, Mekle R, Gruetter R, Cowen P, Jezzard P (2013) Unedited in vivo detection and quantification of γ-aminobutyric acid in the occipital cortex using short-TE MRS at 3T. NMR Biomed. doi: 10.1002/nbm.2960 PubMedGoogle Scholar
  14. Ng F, Berk M, Dean O, Bush AI (2008) Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11:851–876. doi: 10.1017/S1461145707008401 PubMedCrossRefGoogle Scholar
  15. Pizzagalli DA (2011) Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 36:183–206. doi: 10.1038/npp.2010.166 PubMedCrossRefGoogle Scholar
  16. Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672–679PubMedCrossRefGoogle Scholar
  17. Raffa M, Barhoumi S, Atig F, Fendri C, Kerkeni A, Mechri A (2012) Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog Neuropsychopharmacol Biol Psychiatry 39:371–375. doi: 10.1016/j.pnpbp.2012.07.013 PubMedCrossRefGoogle Scholar
  18. Scherk H, Backens M, Schneider-Axmann T, Usher J, Kemmer C, Reith W, Falkai P, Gruber O (2009) Cortical neurochemistry in euthymic patients with bipolar I disorder. World J Biol Psychiatry 10:285–294. doi: 10.3109/15622970701472086 PubMedCrossRefGoogle Scholar
  19. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33PubMedGoogle Scholar
  20. Spielberger CD, Gorsuch RL, Lushene PR, Vagg PR, Jacobs GA (1983) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Inc., Palo Alto, CaGoogle Scholar
  21. Yildiz-Yesiloglu A, Ankerst DP (2006) Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 30:969–995PubMedCrossRefGoogle Scholar
  22. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435PubMedCrossRefGoogle Scholar
  23. Yüksel C, Öngür D (2010) Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 68:785–794. doi: 10.1016/j.biopsych.2010.06.016 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Beata R. Godlewska
    • 1
  • Sarah W. Yip
    • 1
  • Jamie Near
    • 1
    • 2
  • Guy M. Goodwin
    • 1
  • Philip J. Cowen
    • 1
  1. 1.University Department of Psychiatry, Warneford HospitalOxfordUK
  2. 2.FMRIB Centre, Department of Clinical NeurologyUniversity of OxfordOxfordUK

Personalised recommendations